Atyr Pharma
Open
$0.44
Prev. Close
$0.44
High
$0.44
Low
$0.44
Market Snapshot
$43.18M
-0.6
-0.86
$235K
59
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. The company is headquartered in San Diego, California and currently employs 56 full-time employees. The company went IPO on 2015-05-07. The firm is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. The company is headquartered in San Diego, California and currently employs 56 full-time employees. The company went IPO on 2015-05-07. The firm is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
Recently from Cashu
aTyr Pharma Advances Phase III Trial for Efzofitimod in Pulmonary Sarcoidosis Treatment
aTyr Pharma (Ticker: ATYR) is making significant strides in the treatment of pulmonary sarcoidosis with its upcoming Phase III clinical trial for efzofitimod. A New Clinical Trial Phase for efzofitimo…
aTyr Pharma Launches Phase III Trial for Efzofitimod in Pulmonary Sarcoidosis Treatment
aTyr Pharma (Ticker: ATYR) is set to initiate a new Phase III clinical trial for its drug efzofitimod, specifically aimed at treating pulmonary sarcoidosis after receiving feedback from the U.S. Food…
Atyr Pharma Innovates Rare Disease Treatments with Promising Developments in Biologics
Atyr Pharma Advances in Rare Disease Treatment Through Innovative Biologic Platform Atyr Pharma, a clinical-stage biopharmaceutical company, continues to make strides in developing treatments for rare…
Atyr Pharma Secures Funding to Advance Innovative Treatments for Rare Diseases
Atyr Pharma Secures New Funding for Groundbreaking Therapeutic Development Atyr Pharma, a biotherapeutics company developing innovative treatments for rare diseases, announces a significant milestone…